Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2027 (USD Billion)
1.2.1. Myasthenia Gravis Treatment Market, by Treatment, 2019-2027 (USD Billion)
1.2.2. Myasthenia Gravis Treatment Market, by End-Use, 2019-2027 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Myasthenia Gravis Treatment Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Myasthenia Gravis Treatment Market Dynamics
3.1. Myasthenia Gravis Treatment Market Impact Analysis (2019-2027)
3.1.1. Market Drivers
3.1.1.1. Increasing awareness for the autoimmune diseases
3.1.1.2. Growth of biologics and biosimilars industry
3.1.2. Market Challenges
3.1.2.1. Lack of awareness for Myasthenia Gravis disease
3.1.3. Market Opportunities
3.1.3.1. Growing research in causes and treatment of Myasthenia Gravis
Chapter 4. Global Myasthenia Gravis Treatment Market Industry Analysis
4.1. Porter's 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter's 5 Force Model (2018-2027)
4.2. PEST Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.3. Investment Adoption Model
4.4. Analyst Recommendation & Conclusion
Chapter 5. Global Myasthenia Gravis Treatment Market, by Treatment
5.1. Market Snapshot
5.2. Global Myasthenia Gravis Treatment Market by Treatment, Performance - Potential Analysis
5.3. Global Myasthenia Gravis Treatment Market Estimates & Forecasts by Treatment 2018-2027 (USD Billion)
5.4. Myasthenia Gravis Treatment Market, Sub Segment Analysis
5.4.1. Medication Market
5.4.2. Surgery Market
5.4.3. Others Market
Chapter 6. Global Myasthenia Gravis Treatment Market, by End-Use
6.1. Market Snapshot
6.2. Global Myasthenia Gravis Treatment Market by End-Use, Performance - Potential Analysis
6.3. Global Myasthenia Gravis Treatment Market Estimates & Forecasts by End-Use 2018-2027 (USD Billion)
6.4. Myasthenia Gravis Treatment Market, Sub Segment Analysis
6.4.1. Hospitals Market
6.4.2. Clinics Market
6.4.3. Others Market
Chapter 7. Global Myasthenia Gravis Treatment Market, Regional Analysis
7.1. Myasthenia Gravis Treatment Market, Regional Market Snapshot
7.2. North America Myasthenia Gravis Treatment Market
7.2.1. U.S. Myasthenia Gravis Treatment Market
7.2.1.1. Treatment breakdown estimates & forecasts, 2018-2027
7.2.1.2. End-Use breakdown estimates & forecasts, 2018-2027
7.2.2. Canada Myasthenia Gravis Treatment Market
7.3. Europe Myasthenia Gravis Treatment Market Snapshot
7.3.1. U.K. Myasthenia Gravis Treatment Market
7.3.2. Germany Myasthenia Gravis Treatment Market
7.3.3. France Myasthenia Gravis Treatment Market
7.3.4. Spain Myasthenia Gravis Treatment Market
7.3.5. Italy Myasthenia Gravis Treatment Market
7.3.6. Rest of Europe Myasthenia Gravis Treatment Market
7.4. Asia-Pacific Myasthenia Gravis Treatment Market Snapshot
7.4.1. China Myasthenia Gravis Treatment Market
7.4.2. India Myasthenia Gravis Treatment Market
7.4.3. Japan Myasthenia Gravis Treatment Market
7.4.4. Australia Myasthenia Gravis Treatment Market
7.4.5. South Korea Myasthenia Gravis Treatment Market
7.4.6. Rest of Asia Pacific Myasthenia Gravis Treatment Market
7.5. Latin America Myasthenia Gravis Treatment Market Snapshot
7.5.1. Brazil Myasthenia Gravis Treatment Market
7.5.2. Mexico Myasthenia Gravis Treatment Market
7.6. Rest of The World Myasthenia Gravis Treatment Market
Chapter 8. Competitive Intelligence
8.1. Top Market Strategies
8.2. Company Profiles
8.3. Alexion Pharmaceutical Inc.
8.3.1.1. Key Information
8.3.1.2. Overview
8.3.1.3. Financial (Subject to Data Availability)
8.3.1.4. Product Summary
8.3.1.5. Recent Developments
8.3.2. Grifols SA
8.3.3. Avadel Pharmaceuticals, Plc.
8.3.4. Novartis
8.3.5. Pfizer, Inc.
8.3.6. AbbVie Inc.
8.3.7. F.Hoffmann-La Roche AG
8.3.8. GlaxoSmithKline Plc.
8.3.9. Bausch Health Companies Inc.
8.3.10. Shire plc
Chapter 9. Research Process
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes
9.3. Research Assumption